Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effect of the H1-antihistamine clemastine on PACAP38 induced migraine

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PACAP27 induces migraine-like attacks in migraine patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Neck pain and headache after whiplash injury: a systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: To investigate the effect of the H1-antihistamine clemastine on the migraine-inducing abilities of pituitary adenylate cyclase activating peptide-38. Methods: We conducted a double-blind, randomized, placebo controlled two-way cross-over study. Twenty migraine without aura patients were randomly allocated to receive bolus clemastine 2 mg (1 mg/ml) or bolus saline 2 ml intravenously over 2 min on two study days. Following each bolus injection, 10 pmol/kg/min of pituitary adenylate cyclase activating peptide-38 was administered intravenously over 20 min. We recorded migraine/headache characteristics every 10 min until 90 min after the start of infusion, and collected blood to investigate mast cell degranulation and the inflammation markers tryptase and tumor necrosis factor-alpha before and after infusion of pituitary adenylate cyclase activating peptide-38. Results: After clemastine pretreatment, five out of 20 participants developed a migraine-like attack in response to a pituitary adenylate cyclase activating peptide-38 infusion compared to nine out of 20 after placebo pretreatment (p = 0.288). Following clemastine pretreatment, 15 out of 20 participants reported headache in response to a pituitary adenylate cyclase activating peptide-38 infusion, whereas 19 out of 20 participants did so following placebo pretreatment (p = 0.221). We found no difference in area under the curve 12 h for headache intensity between the two experimental days (p = 0.481). We found no difference in area under the curve 180 min for tryptase (p = 0.525) or tumor necrosis factor-alpha (p = 0.487) between clemastine and placebo pretreatment days. Conclusion: H1-antihistamine, clemastine, failed to prevent migraine or headache after pituitary adenylate cyclase activating peptide-38 infusion, thus making a role for histamine release or mast cell degranulation in pituitary adenylate cyclase activating peptide-38-induced migraine less likely.

Original languageEnglish
JournalCephalalgia
Volume39
Issue number5
Pages (from-to)597-607
Number of pages11
ISSN0333-1024
DOIs
Publication statusPublished - Apr 2019

    Research areas

  • antihistamine, mast cells, migraine, PAC receptor, PACAP38

ID: 55587608